AltMountain

Sivik Global Healthcare, LLC

Location not listed · CRD 168918
Hedge fund manager

Sivik Global Healthcare, LLC is an SEC-registered investment adviser that reports managing 1 hedge fund on Form ADV. It reports $233.9 million in regulatory assets under management. Its private funds, of all types, hold $233.9 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +3.5% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +13.2% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$233.9 millionForm ADV Item 5.F
Gross assets of private funds
$233.9 millionAll private fund types, Form ADV
Hedge funds managed
11 private funds in total
Employees
3Form ADV Item 5.A
Registration
SEC-registered adviserCRD 168918
Latest Form ADV
02/17/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+3.5%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+13.2%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$131.7 million34 positions, 2026-06-30
$93$115$137Q3 2024Q1 2025Q3 2025Q1 202613F est. $113S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+9.7%+14.8%
Q1 2026-5.6%-4.6%
Q4 2025+7.9%+2.4%
Q3 2025+3.1%+7.8%
Q2 2025+2.9%+10.4%
Q1 2025+3.2%-4.5%
Q4 2024-11.7%+2.1%
Q3 2024+4.8%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 35 share positions ($175,040,173) reported by Sivik Global Healthcare LLC on Form 13F for the quarter ended Sep 30, 2026, filed Oct 13, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • SPDR Series Trust16.21%
  • Humana Inc3.86%
  • Johnson & Johnson3.63%
  • Merck & Co Inc3.32%
  • Abbvie Inc3.29%
  • Thermo Fisher Scientific Inc3.28%
  • Cardinal Health Inc3.18%
  • Mckesson Corp3.17%
  • Danaher Corp Del3.16%
  • Unitedhealth Group Inc3.15%
StockValue% of 13F portfolioSharesShares vs prior quarter
SPDR Series Trust$28,382,40016.21%180,000+20.00%
Humana Inc$6,753,7893.86%17,700-11.50%
Johnson & Johnson$6,353,7603.63%24,000+20.00%
Merck & Co Inc$5,812,4003.32%40,000Unchanged
Abbvie Inc$5,754,9803.29%22,000+46.67%
Thermo Fisher Scientific Inc$5,737,9253.28%8,500+6.25%
Cardinal Health Inc$5,562,5003.18%25,000+4.17%
Mckesson Corp$5,549,7653.17%6,500+62.50%
Danaher Corp Del$5,538,7503.16%25,000+25.00%
Unitedhealth Group Inc$5,506,2003.15%15,000+50.00%
Vertex Pharmaceuticals Inc$5,489,5053.14%10,500+5.00%
Elevance Health Inc Formerly$5,443,4803.11%14,000+180.00%
Abbott Laboratories$5,435,6503.11%55,000+120.00%
Cencora Inc$5,404,5003.09%18,000+20.00%
Agilent Technologies Inc$5,169,3002.95%30,000Unchanged
Centene Corp Del$4,969,6002.84%80,000New
Eli Lilly & Co$4,894,4482.80%4,230-15.40%
Encompass Health Corp$4,859,6002.78%40,000+166.67%
Revvity Inc$4,586,7002.62%30,000New
Waters Corp$4,393,9002.51%10,000-33.33%
Bruker Corp$4,208,7502.40%65,000New
Edwards Lifesciences Corp$3,884,4002.22%45,000+125.00%
Medtronic PLC$3,883,0502.22%45,000New
Repligen Corp$3,844,6002.20%20,000New
Mettler Toledo International$3,777,3752.16%2,500-9.09%
Gilead Sciences Inc$3,726,2502.13%25,000Unchanged
The Cigna Group$3,588,9712.05%13,203New
Biogen Inc$3,388,2001.94%15,000Unchanged
Bio Rad Labs Inc$3,021,6801.73%8,000-20.00%
Avantor Inc$2,633,7501.50%175,000New
Biontech SE$2,162,6001.24%22,000New
Moderna Inc$1,925,7001.10%10,000New
Argenx SE$1,917,8201.10%2,000New
Madrigal Pharmaceuticals Inc$1,259,9000.72%2,500New
Twist Bioscience Corp$217,9750.12%1,128New

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 12 new positions, 11 sold out, 14 increased, 5 reduced and 4 unchanged.

Number of positions (a count, not dollars)

  • New positions12
  • Increased14
  • Unchanged4
  • Reduced5
  • Sold out11

New positions

StockValueShares
Centene Corp Del$4,969,60080,000
Revvity Inc$4,586,70030,000
Bruker Corp$4,208,75065,000
Medtronic PLC$3,883,05045,000
Repligen Corp$3,844,60020,000
The Cigna Group$3,588,97113,203
Avantor Inc$2,633,750175,000
Biontech SE$2,162,60022,000
Moderna Inc$1,925,70010,000
Argenx SE$1,917,8202,000
Madrigal Pharmaceuticals Inc$1,259,9002,500
Twist Bioscience Corp$217,9751,128

Sold out

StockValue at Jun 30, 2026Shares held then
Call- BSX 100 @ 75 Exp 04/17/2026$5,020,000800
Intuitive Surgical Inc$4,149,0009,000
Astrazeneca PLC$3,944,00020,000
Boston Scientific Corp$3,891,00062,000
Tenet Healthcare Corp$3,774,00020,000
Stryker Corporation$3,286,00010,000
Universal Hlth Svcs Inc$3,132,00017,500
Regeneron Pharmaceuticals$3,091,0004,000
Globus Med Inc$2,585,00030,000
Smith & Nephew PLC$1,589,00050,000
CVS Health Corp$1,436,00020,000

Largest increases

StockChange in sharesChangeValue nowShares now
SPDR Series Trust+30,000+20.00%$28,382,400180,000
Elevance Health Inc Formerly+9,000+180.00%$5,443,48014,000
Encompass Health Corp+25,000+166.67%$4,859,60040,000
Abbott Laboratories+30,000+120.00%$5,435,65055,000
Edwards Lifesciences Corp+25,000+125.00%$3,884,40045,000
Mckesson Corp+2,500+62.50%$5,549,7656,500
Unitedhealth Group Inc+5,000+50.00%$5,506,20015,000
Abbvie Inc+7,000+46.67%$5,754,98022,000
Danaher Corp Del+5,000+25.00%$5,538,75025,000
Johnson & Johnson+4,000+20.00%$6,353,76024,000
Cencora Inc+3,000+20.00%$5,404,50018,000
Thermo Fisher Scientific Inc+500+6.25%$5,737,9258,500
Vertex Pharmaceuticals Inc+500+5.00%$5,489,50510,500
Cardinal Health Inc+1,000+4.17%$5,562,50025,000

Largest reductions

StockChange in sharesChangeValue nowShares now
Waters Corp-5,000-33.33%$4,393,90010,000
Eli Lilly & Co-770-15.40%$4,894,4484,230
Humana Inc-2,300-11.50%$6,753,78917,700
Bio Rad Labs Inc-2,000-20.00%$3,021,6808,000
Mettler Toledo International-250-9.09%$3,777,3752,500

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (1)

As reported in the adviser's Form ADV filed Feb 29, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​‌​⁠